RevBio Gains Funds to Support Bone Adhesive for Wrist Fracture

RevBio Tetranite Bone Adhesive

RevBio was awarded a two-year, $2 million Phase II Small Business Innovation Research to pursue the treatment of wrist fractures with its Tetranite® bone adhesive technology. The injectable adhesive requires only a small incision to deliver the material, making it a more minimally invasive treatment option than standard open surgery.


document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us